News
Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...
In recently reported case studies, nemolizumab, approved for two indications associated with itch, has been reported to be ...
Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease ...
Eli Lilly and Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group ...
23h
Zacks Investment Research on MSNEli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on ItEli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...
Explore more
Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products ...
Officials with the Indianapolis Public Schools recently announced that the district will receive more than $10 million from ...
INDIANAPOLIS, July 25, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston ...
The European Medicines Agency has granted restricted EU authorization to Eli Lilly’s Alzheimer’s drug Kisunla, reversing an ...
8h
The Print on MSNIndia sees 20k bariatric surgeries a year. But blockbusters Mounjaro, Wegovy are shaking up obesity arenaIndia's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...
Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results